IP Verse

Novel Immune Checkpoint Inhibitors - EP3802922

The patent EP3802922 was granted to Boehringer Ingelheim on Apr 26, 2023. The application was originally filed on Jun 10, 2019 under application number EP19740098A. The patent is currently recorded with a legal status of "Revoked".

EP3802922

BOEHRINGER INGELHEIM
Application Number
EP19740098A
Filing Date
Jun 10, 2019
Status
Revoked
May 2, 2025
Grant Date
Apr 26, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJan 26, 2024VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTCN102393456B
INTERNATIONAL-SEARCH-REPORTCN110029168
INTERNATIONAL-SEARCH-REPORTKR20150037321
INTERNATIONAL-SEARCH-REPORTWO2010019570
INTERNATIONAL-SEARCH-REPORTWO2015042246
INTERNATIONAL-SEARCH-REPORTWO2017078318
INTERNATIONAL-SEARCH-REPORTWO2019141092
OPPOSITIONWO2010019570
OPPOSITIONWO2014008218
OPPOSITIONWO2015042246
OPPOSITIONWO2019241098

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- CREG J WORKMAN ET AL, "Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, (20020726), vol. 32, no. 8, doi:10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A, ISSN 0014-2980, pages 2255 - 2263, XP071222330
OPPOSITION- Anonymous, "Affinity Purified anti-mouse CD223 (LAG3, LAG-3) ", eBioscience, (20080516), eBioscience, URL: https://web.archive.org/web/20080516230215/http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2231.htm, XP093159121-
OPPOSITION- Anonymous, "History of Changes for Study: NCT02935634 A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC", Clinical trials.gov NCT02935634, (20180507), Clinical trials.gov NCT02935634, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02935634?V_27=View%23StudyPageTop, XP093159117-
OPPOSITION- P.A. Ascierto et al., "Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progresssed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched...", Annals of Oncology (Developmental Therapeutics), (201709), vol. 28, page 5-
OPPOSITION- Creg J. Workman; Dennis S. Rice; Kari J. Dugger; Cornelia Kurschner; Dario A. A. Vignali, "Phenotypic analysis of the murine CD4‐related glycoprotein, CD223 (LAG‐3)", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20020726), vol. 32, no. 8, doi:10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A, ISSN 0014-2980, pages 2255 - 2263, XP071222330
OPPOSITION- Maruhashi Takumi; Sugiura Daisuke; Okazaki Il-mi; Shimizu Kenji; Maeda Takeo K.; Ikubo Jun; Yoshikawa Harunori; Maenaka Katsumi; Ishimaru Naozumi; Kosako Hidetaka; Takemoto Tatsuya; Okazaki Taku, "Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20220411), vol. 55, no. 5, doi:10.1016/j.immuni.2022.03.013, ISSN 1074-7613, page 912, XP087050461
OPPOSITION- Shawn D Blackburn, Shin Haina, Haining W Nicholas, Zou Tao, Workman Creg J, Polley Antonio, Betts Michael R, Freeman Gordon J, Vignali Dario A A, Wherry E John, "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection", Nature Immunology, Nature America Inc., (20090101), vol. 10, no. 1, doi:10.1038/ni.1679, ISSN 15292908, pages 29 - 37, XP055047746
OPPOSITION- HUARD B., ET AL., "CHARACTERIZATION OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II BINDING SITE ON LAG-3 PROTEIN.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19970501), vol. 94., no. 11., doi:10.1073/pnas.94.11.5744, ISSN 0027-8424, pages 5744 - 5749., XP002037067
OPPOSITION- Markus Zettl, "Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses", Oncoimmunolgy, Landes Bioscience, US, US , (20221231), vol. 11, no. 1, doi:10.1080/2162402X.2022.2080328, ISSN 2162-4011, XP093159105
OPPOSITION- Lawrence P. Andrews; Ariel E. Marciscano; Charles G. Drake; Dario A. A. Vignali, "LAG3 (CD223) as a cancer immunotherapy target", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20170304), vol. 276, no. 1, doi:10.1111/imr.12519, ISSN 0105-2896, pages 80 - 96, XP071455990
OPPOSITION- Patrick Schöffski, "Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB , (20220201), vol. 10, no. 2, doi:10.1136/jitc-2021-003776, ISSN 2051-1426, page e003776, XP093159113
OPPOSITION- Kent Thudium, "Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab", Cancer Immunology Research, American Association for Cancer Research, US, US , (20221004), vol. 10, no. 10, doi:10.1158/2326-6066.CIR-22-0057, ISSN 2326-6066, pages 1175 - 1189, XP093159107
OPPOSITION- Saso Cemerski;Shuxia Zhao;Melissa Chenard;Jason Laskey;Long Cui;Rinkan Shukla;Brian Haines;Edward Hsieh;Maribel Beaumont;Jeanine Mattson;Wendy Blumenschein;Heather Hirsch;Laurence Fayadat-Dilman;Linda Liang;Rene De Waal Malefyt, "T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 - MHCII blocking capacity", Journal for ImmunoTherapy of Cancer, BioMed Central Ltd, London, UK, London, UK , (20151104), vol. 3, no. 2, doi:10.1186/2051-1426-3-S2-P183, pages 1 - 1, XP021235237
OPPOSITION- Yang Zhang, "Fibrinogen‑like‑protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis", Molecular Medicine Reports, Spandidos Publications, GR, GR , (20180529), vol. 18, doi:10.3892/mmr.2018.9097, ISSN 1791-2997, pages 1465 - 1472, XP093159110
OPPOSITION- Workman Creg J., Vignali Dario A. A., "Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)", The Journal of Immunology, Williams & Wilkins Co., US, US , (20050115), vol. 174, no. 2, doi:10.4049/jimmunol.174.2.688, ISSN 0022-1767, pages 688 - 695, XP055795103

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents